跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,120 条关于
“CDK4/6i”
全部
1,120
临床试验
659
药物
186
机构
0
资讯
275
去年
NCCN Guidelines Recognize Novartis' Ribociclib as Category 1 Preferred Adjuvant Therapy for HR+/HER2- Early Breast Cancer
去年
Ribociclib Gains NCCN Recommendation as Preferred Adjuvant Therapy for Early Breast Cancer
去年
Tempus Presents New Breast Cancer Research at SABCS 2024, Highlighting AI-Driven Precision Medicine
去年
Genor Biopharma Secures NMPA Approval for Lerociclib CDK4/6 Inhibitor in Advanced Breast Cancer
去年
Lilly's Imlunestrant Phase 3 EMBER-3 Data to be Presented at SABCS 2024
去年
Incyclix Bio Raises $11.25 Million to Advance CDK2 Inhibitor INX-315 for Treatment-Resistant Breast and Ovarian Cancers
去年
Biovica Partners with Tempus to Expand Access to DiviTum TKa Blood Test for Metastatic Breast Cancer Monitoring
5年前
CDK4/6 Inhibitors Show Potential in HR+/HER2- Early Breast Cancer Adjuvant Therapy
4个月前
Avenzo Therapeutics Initiates CDK4/CDK2 Dual Inhibitor Combination Trial for HR+/HER2- Breast Cancer
去年
Machine Learning Model Predicts CDK4/6 Inhibitor Response in Metastatic Breast Cancer
第 1 页,共 28 页
上一页
下一页